LY-CoV555 and LY-CoV016 are two SARS-CoV-2 neutralizing antibodies which bind
complementary regions of the SARS-CoV-2 spike protein. Studies are investigating
their use in monotherapy and in combination. Only interim results are available
at this time.
|
|
|
|
|
|
|
Positive
|
Early |
Lilly (Preprint) |
hosp., ↓84.5%, p=0.05 |
SARS-CoV-2 neutralizing antibody program update |
| Interim results from the BLAZE-1 outpatient RCT showing improvements in viral load, symptoms and hospitalization.
Combination therapy significantly reduced viral load at day 11 (p=0.011). A greater effect is seen at day 7 (p<0.001). The .. |
|
Positive
|
Early treatment study
|
| Lilly (Preprint) |
| SARS-CoV-2 neutralizing antibody program update |
Interim results from the BLAZE-1 outpatient RCT showing improvements in viral load, symptoms and hospitalization.Combination therapy significantly reduced viral load at day 11 (p=0.011). A greater effect is seen at day 7 (p<0.001). The proportion of patients with persistent high viral load at day 7 for combination therapy was lower (3.0 percent) versus placebo (20.8 percent), corresponding to a nominal p value of p<0.0001 without multiplicity adjustment. No emergent putative resistance variants have been observed thus far in patients treated with combination therapy.The rate of COVID-related hospitalization and ER visits was lower for patients treated with combination therapy (0.9 percent) versus placebo (5.8 percent), a relative risk reduction of 84.5 percent (p=0.049). This was also similar to observations for LY-CoV555 monotherapy.Combination therapy has been generally well tolerated with no drug-related serious adverse events. In LY-CoV555 monotherapy studies there have been isolated drug-related infusion reactions or hypersensitivity that were generally mild (two reported as serious infusion reactions, all patients recovered).NCT04427501
![]()
hospitalization, ↓84.5%, p=0.05, hospitalization/ER
|
|
Source
Study Page
Submit Corrections or Comments
|
Please send us corrections, updates, comments.
Submit
